These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25611491)
1. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491 [No Abstract] [Full Text] [Related]
2. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648 [TBL] [Abstract][Full Text] [Related]
3. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285 [TBL] [Abstract][Full Text] [Related]
4. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295 [No Abstract] [Full Text] [Related]
5. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149 [No Abstract] [Full Text] [Related]
6. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Park SH; Chi HS; Cho YU; Jang S; Park CJ Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719 [TBL] [Abstract][Full Text] [Related]
10. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010 [No Abstract] [Full Text] [Related]
11. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia. Zhang Q; Bai S; Vance GH Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693 [TBL] [Abstract][Full Text] [Related]
12. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467 [TBL] [Abstract][Full Text] [Related]
13. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H; N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602 [TBL] [Abstract][Full Text] [Related]
14. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort. Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268 [TBL] [Abstract][Full Text] [Related]
16. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. Bacher U; Haferlach T; Alpermann T; Kern W; Schnittger S; Haferlach C Leukemia; 2013 Feb; 27(2):496-500. PubMed ID: 22858909 [No Abstract] [Full Text] [Related]
17. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848 [TBL] [Abstract][Full Text] [Related]
18. Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. Zhang Y; Wang F; Chen X; Liu W; Fang J; Wang M; Teng W; Cao P; Liu H Front Med; 2019 Apr; 13(2):229-237. PubMed ID: 29806051 [TBL] [Abstract][Full Text] [Related]